GlassScriptPhysician profile
Yi T Liu
NPI 1871706242
$5,233.03
in general payments reported to CMS, 2019-2025
9 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,021 · 2022: $1,004 · 2023: $1,142 · 2024: $1,599 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,198 · Education: $10.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,197.89 |
| Education | $10.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,295.94 | 2021-2025 | Biktarvy, Descovy |
| Viiv Healthcare Company | $1,187.84 | 2021-2025 | Dovato, Cabenuva |
| Janssen Biotech, INC. | $474.33 | 2021-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $404.33 | 2021-2025 | Delstrigo, Pifeltro, Zerbaxa |
| Emd Serono, INC. | $295.52 | 2021-2024 | Serostim |
| Napo Pharmaceuticals INC | $245.59 | 2021-2023 | Mytesi |
| Janssen Products, LP | $198.95 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $119.79 | 2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $10.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.